India There were 16,299 Kovid cases and 53 deaths on Thursday. The cumulative caseload stands at 4,42,06,996 (1,25,076 active cases) and 5,26,879 deaths
Whole world: Over 587 million cases and over 6.42 million deaths.
vaccination In India: Over 2.07 billion doses. Worldwide: over 12.01 billion doses.
Official sources said on Wednesday that the government has approved the organic E’s Corbevax as a precautionary dose for adults who have taken Covishield or two jabs of Covaxin.
This is the first time that the country has allowed a booster dose different from the booster dose used for the primary vaccination series. It can reportedly be taken up to six months after receiving the second dose.
Sources said this would be in addition to the existing guidelines for home precautionary dosage administration of Covaxin and Covishield vaccines.
India’s first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to vaccinate children in the age group of 12 to 14 years as part of the COVID-19 vaccination programme. So far, approximately 6.85 crore doses of Corbevax have been administered to adolescents.
The COVID-19 Working Group (CWG), at its July 20 meeting, reviewed data from a double-blind randomized phase-3 clinical study showing immunity to a booster dose of Corbevax vaccine when fully vaccinated against a COVID-negative And safety was assessed. Volunteer
The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as an asymptomatic precautionary dose, but the government was waiting for the recommendations of the National Technical Advisory Group on Immunization (NTAGI) before giving its approval.
India began giving precautionary doses of vaccines to health care and frontline workers and people aged 60 and above from January 10.
A number of variants of concern (VOCs) and interest have emerged since the pandemic began and by all indications, the alphabet soup is poised to advance, although predicting the frequency and direction of future mutations remains a challenge.
one in new studyResearchers at Columbia University Mailman School of Public Health analyzed the transmission dynamics of existing variants and discovered shared traits associated with transmissibility and immune evasion.
the study: The team developed a mathematical model using weekly case and death data from nine South African provinces from March 2020 to the end of February 2022 to reconstruct SARS-CoV-2 transmission dynamics.
Their model was validated using three independent datasets. It found that the estimated cumulative infection rate over time roughly corresponds to serology data, and the estimated number of infections corresponds to the number of hospitalizations for all four epidemic waves in the country.
conclusion: the study, published In elife The journal highlights the need for more proactive planning and preparedness for future VOCs, including the development of a universal vaccine that can prevent SARS-CoV-2 infection as well as prevent severe disease.
They found that the beta version destroyed immunity in about 65% of people previously infected with the parental SARS-CoV-2 and was 35% more transmissible than the original virus.
Delta estimates varied from province to province, but overall, the variant destroyed immunity by about 25% from prior infection or vaccination and was 50% more transmissible. This aligns with the 27.5% re-infection rate observed during the delta wave in Delhi, India.
The team also estimated that Omicron was about 95% more transmitted than the parental SARS-CoV-2 and elicited immunity by 55% (prior infection and vaccination).
Meaning: These results suggest that high prior immunity to SARS-CoV-2 does not prevent new COVID-19 outbreaks, as neither prior infection nor current vaccination completely prevents infection from a new variant. So don’t be in a hurry to give up face masks and other pandemic protocols.
Follow the news important to you in real time. Join 3 crore news lovers.
written by: Rakesh Rai, Sushmita Chaudhary, Jayant Kalita, Prabhas K Dutta research: Rajesh Sharma